Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 98
Filter
3.
Rev. bras. ortop ; 57(2): 200-206, Mar.-Apr. 2022. tab, graf
Article in English | LILACS | ID: biblio-1388002

ABSTRACT

Abstract Bone metastases may evolve with events (pain, fractures and compression) that the orthopedic surgeon will encounter regardless of his subspecialty. Accumulated surgical knowledge is predictive for the prevention of impending fractures, as well as of pathological fractures. We will present a guide to properly evaluate and conduct a patient with bone implant for surgeons who are not specialists in this area.


Resumo As metástases ósseas podem evoluir com eventos (dor, fraturas e compressão) com os quais o cirurgião ortopédico irá se depararar independentemente da sua subespecialidade. Os conhecimentos cirúrgicos acumulados são predicativos para a prevenção de fraturas iminentes, assim como de fraturas patológicas. Apresentaremos um guia para avaliar e conduzir de forma adequada um paciente com implante ósseo para cirurgiões que não sejam especialistas na área.


Subject(s)
Humans , Bone Neoplasms/therapy , Carcinoma/therapy , Fractures, Bone/prevention & control , Fractures, Bone/therapy , Neoplasm Metastasis/therapy
4.
Rev. bras. ginecol. obstet ; 44(1): 32-39, Jan. 2022. tab, graf
Article in English | LILACS | ID: biblio-1365675

ABSTRACT

Abstract Objective To evaluate the improvement in screening accuracy of the Fracture Risk Assessment Tool (FRAX) for the risk of developing osteoporosis among young postmenopausal women by associating with it clinical muscle mass measures. Methods A sample of postmenopausal women was submitted to calcaneal quantitative ultrasound (QUS), application of the FRAX questionnaire, and screening for the risk of developing sarcopenia at a health fair held in the city of São Bernardo do Campo in 2019. The sample also underwent anthropometric measurements, muscle mass, walking speed and handgrip tests. A major osteoporotic fracture (MOF) risk ≥ 8.5% on the FRAX, a classification of medium risk on the clinical guideline of the National Osteoporosis Guideline Group (NOGG), and a QUS T-score ≤ -1.8 sd were considered risks of having low bone mass, and QUS T-score ≤ -2.5sd, risk of having fractures. Results In total, 198 women were evaluated, with a median age of 64±7.7 years, median body mass index (BMI) of 27.3±5.3 kg/m2 and median QUS T-score of -1.3±1.3 sd. The accuracy of the FRAX with a MOF risk ≥ 8.5% to identify women with T-scores ≤ -1.8 sd was poor, with an area under the curve (AUC) of 0.604 (95% confidence interval [95%CI]: 0.509-0.694) for women under 65 years of age, and of 0.642 (95%CI: 0.571-0.709) when age was not considered. Including data on muscle mass in the statistical analysis led to a significant improvement for the group of women under 65 years of age, with an AUC of 0,705 (95%CI: 0.612-0.786). The ability of the high-risk NOGG tool to identify T-scores ≤ -1.8 sd was limited. Conclusion Clinical muscle mass measurements increased the accuracy of the FRAX to screen for osteoporosis in women aged under 65 years.


Resumo Objetivo Avaliar a melhora da precisão da Fracture Risk Assessment Tool (Ferramenta de Avaliação do Risco de Fraturas, FRAX, em inglês) no rastreio do risco de desenvolver osteoporose em mulheres jovens pós-menopáusicas com a associação de medidas clínicas de massa muscular e preensão manual. Métodos Uma amostra de mulheres pós-menopáusicas foi submetida a ultrassom quantitativo (USQ) de calcâneo, à aplicação do questionário FRAX, e rastreadas quanto ao risco de desenvolver sarcopenia em uma feira de saúde realizada em 2019 em São Bernardo do Campo. Alémdisso, a amostra tambémfoi submetida a antropometria, e a testes de massa muscular, velocidade de marcha, e preensão manual. Um risco de grandes fraturas osteoporóticas (GFOs) ≥ 8,5% no FRAX, classificação de médio risco nas diretrizes clínicas do National Osteoporosis Guideline Group (NOGG), e T-score no USQ ≤ -1,8 dp foram considerados riscos de ter baixa massa óssea, e T-score no QUS ≤ -2,5 sd, risco de ter fraturas. Resultados Ao todo, 198 mulheres foram avaliadas, com idade média de 64±7,7 anos, índice de massa corporal (IMC) médio de 27,3±5,3 kg/m2, e T-score médio no USQ de -1,3±1,3 sd. A precisão do FRAX comumrisco de GFO≥ 8,5% para identificar mulheres com T-score ≤ -1,8 dp foi precária, com uma área sob a curva (ASC) de 0,604 (intervalo de confiança de 95% [IC95%]: 0,509-0,694), para mulheres menores de 65 anos de idade, e de 0,642 (IC95%: 0,571-0,709) quando a idade não foi considerada. A inclusão de dados da massa muscular na análise estatística levou a uma melhora significativa no grupo menor de 65 anos de idade, com uma ASC de 0,705 (IC95%: 0,612-0,786). A habilidade da ferramenta NOGG de alto risco para identificar T-scores ≤ -1,8 dp foi limitada. Conclusão As medidas clínicas da massa muscular aumentaram a precisão do FRAX no rastreio de osteoporose em mulheres menores de 65 anos de idade.


Subject(s)
Humans , Female , Osteoporosis/therapy , Menopause, Premature , Fractures, Bone/prevention & control , Sarcopenia
6.
Rev. Ateneo Argent. Odontol ; 66(1): 34-46, 2022. ilus, tab
Article in Spanish | LILACS | ID: biblio-1380253

ABSTRACT

La población mayor de 60 años es el grupo etario de mayor crecimiento en el mundo. Debido a que la depresión es una patología frecuente en la persona adulta mayor y anciana, los inhibidores de la recap- tación de la serotonina (ISRS) son el tratamiento de primera línea de elección. Este trabajo referencia la asociación del consumo de estos fármacos con la disminución de la densidad ósea mineral (DMO), el riesgo de fracturas y su repercusión en la atención odontológica. Además, incluye una breve descripción de la homeostasis ósea y la relación depresión-carga alostática. El trabajo interdisciplinario y una correcta anamnesis pueden detectar posibles complicaciones y riesgos vinculados con este tipo de medicamen- tos. Ello facilitaría un mejor manejo, más aún en el adulto mayor, donde una pequeña variable puede repercutir en su integridad (AU)


The population over 60 is the fastest growing age group in the world. Depression is a frequent pathology in the elderly and the elderly, with serotonin reuptake inhibitors (SSRI) being the 1st line treatment of choice. The association of the consumption of this drug with a decrease in bone mineral density (BMD), risk of fractures and its impact on dental care are referenced in this work. In addition, it includes a brief description of bone homeostasis and the depression-allostatic load relationship. Interdisciplinary work and a correct anamnesis can detect possible complications and risks linked to this type of medication, facilitating better management and even more so in the elderly, where a small variable can affect their integrity (AU)


Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Dental Care for Aged/methods , Selective Serotonin Reuptake Inhibitors/adverse effects , Depression/complications , Antidepressive Agents/adverse effects , Bone Density/drug effects , Dental Implants/adverse effects , Risk Factors , Age Factors , Bone Remodeling/physiology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Dental Restoration Failure , Fractures, Bone/prevention & control , Allostasis , Homeostasis
7.
Actual. osteol ; 17(2): 78-91, 2021. graf, ilus
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1370190

ABSTRACT

La concepción original del mecanostato como un regulador de la rigidez estructural ósea orientado a mantener un determinado 'factor de seguridad' en todos los esqueletos parece no corresponder por igual a cualquier hueso y para cualquier tipo de estímulo. Hemos descubierto que la estructura cortical diafisaria del peroné humano manifiesta un comportamiento ambiguo del sistema, referido al uso del pie. La diáfisis peronea, además de ser insensible al desuso, se rigidiza, como sería de esperar, por entrenamientos en disciplinas deportivas que rotan o revierten el pie (hockey, fútbol, rugby); pero, llamativamente, se flexibiliza en su mitad proximal por entrenamiento en carrera larga, que optimiza el rendimiento del salto que acompaña a cada paso. La referida rigidización robustecería la región peronea de inserción de los músculos que rotan o revierten el pie, favoreciendo la locomoción sobre terrenos irregulares o 'gambeteando', propia de especies predadoras como los leopardos. La 'inesperada' flexibilización proximal, pese a reducir la resistencia a la fractura por flexión lateral (poco frecuente en el hombre), favorecería la absorción elástica de la energía contráctil de la musculatura inserta, optimizando el rendimiento del salto al correr, condición vital para especies presas como las gacelas. La falta de analogía de estas respuestas de la estructura peronea a distintos entrenamientos, incompatible con el mantenimiento de un factor de seguridad, sugiere su vinculación preferencial con la optimización de aptitudes esqueléticas con valor selectivo. Esto ampliaría el espectro regulatorio del mecanostato a propiedades esqueléticas 'vitales', más allá del control de la integridad ósea. Su manifestación en el hombre, ajena a connotaciones selectivas (quizá resultante del mantenimiento de genes ancestrales), permitiría proponer la indicación de ejercicios orientados en direcciones preferenciales a este respecto, especialmente cuando estas coincidieran con las de las fuerzas que podrían fracturar al hueso. (AU)


The original notion of the mechanostat as a regulator of bone structural rigidity oriented to maintain a certain 'safety factor' in all skeletons does not seem to correspond equally to every bone and for any type of stimulus. We have discovered that the diaphyseal cortical structure of the human fibula shows an ambiguous behavior of the system, with reference to the use of the foot. The peroneal shaft, in addition to being insensitive to disuse, becomes stiffened, as might be expected, by training in sport disciplines that involve rotating or reversing the foot (hockey, soccer, rugby); but, remarkably, it becomes more flexible in its proximal half by long-distance running training, which optimizes the performance of the jump that accompanies each step. The stiffening would strengthen the peroneal region of insertion of the muscles that rotate or reverse the foot, favoring locomotion on uneven terrain or 'dribbling', typical of predatory species such as leopards. The 'unexpected' proximal flexibilization, despite reducing the resistance to lateral flexion fracture (rare in human), would favor the elastic absorption of contractile energy from the inserted muscles, optimizing jumping performance when running, a vital condition for prey species such as gazelles. The lack of analogy of these responses of the peroneal structure to different training, incompatible with the maintenance of a safety factor, suggests its preferential link with the optimization of skeletal aptitudes with selective value. This would expand the regulatory spectrum of the mechanostat to 'vital' skeletal properties, beyond the control of bone integrity. Its manifestation in humans, oblivious to selective connotations (perhaps resulting from the maintenance of ancestral genes), would make it possible to propose the indication of exercises oriented in preferential directions, especially when they coincide with the direction of the forces that could fracture the bone. (AU)


Subject(s)
Humans , Animals , Sports/physiology , Bone and Bones/physiology , Exercise/physiology , Fibula/physiology , Foot/physiology , Soccer/physiology , Track and Field/physiology , Biomechanical Phenomena , Fractures, Bone/prevention & control , Fibula/anatomy & histology , Football/physiology , Hockey/physiology
8.
Actual. osteol ; 17(3): 85-94, 2021. ilus
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1395300

ABSTRACT

La osteoporosis de la posmenopausia es una enfermedad crónica y progresiva asociada con un bajo pico de masa ósea o una rápida y persistente pérdida de masa ósea como con-secuencia del déficit de estrógenos endógenos y del envejecimiento. A pesar de que en la actualidad la oferta de medicamentos para su tratamiento en distintas etapas de la vida es muy importante, sigue siendo una enfermedad subdiagnosticada y subtratada a nivel global. La edad, las comorbilidades existentes, los tratamientos concomitantes, el riesgo de caídas, y los antecedentes familiares o personales de fracturas recientes o pasadas tanto como la densidad mineral ósea son factores que deben ser considerados en la evaluación de cada paciente para determinar el grado de riesgo de fractura En aquellos considerados con alto riesgo o riesgo inminente de fractura se recomienda iniciar un tratamiento con algún agente anabólico seguido por un anticatabólico para lograr una rápida reducción del riesgo de fractura. Por último, una adecuada adherencia en el tiempo al tratamiento es clave para alcanzar la mayor eficacia terapéutica dirigida a la reducción de la ocurrencia de fracturas por fragilidad ósea. (AU)


Postmenopausal osteoporosis is a chronic and progressive disease associated with low peak bone mass or a fast and persistent loss of bone mass as a consequence of endogenous estrogen deficiency and aging, and it is an underdiagnosed and undertreated disease worldwide. At present, there is a wide range of drugs available for the treatment of postmenopausal osteoporosis, with appropriate treatments for each phase of this stage of a woman's life. All factors that may increase the risk of bone fragility fracture should be considered at the time of patient assessment. These include age, existing comorbidities, concomitant treatments, risk of falling, family history of fractures or recent or past personal history of fractures, and the results of bone mineral density assessment. In those patients at high risk or imminent risk of fracture, it is recommended to start treatment with an anabolic agent followed by an anticatabolic agent, in order to achieve an immediate reduction of fracture risk. Finally, an adequate adherence to treatment over time will allow achieving the greatest effectiveness of the proposed therapy, which is the reduction of bone fragility fracture events. (AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Osteoporosis, Postmenopausal/drug therapy , Treatment Outcome , Fractures, Bone/prevention & control , Medication Adherence , Bone Density , Risk Factors , Teriparatide/therapeutic use , Risk Reduction Behavior , Diphosphonates/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Healthy Lifestyle
9.
Actual. osteol ; 17(3): 71-84, 2021. ilus, tab
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1395384

ABSTRACT

Con el advenimiento de la terapia antirretroviral, el pronóstico y la sobrevida de los pacientes infectados con el virus de la inmunodeficiencia humana (VIH) han cambiado de manera radical, por lo cual en la actualidad se evidencia un aumento en el riesgo de padecer enfermedades no relacionadas con el VIH como, por ejemplo, la osteoporosis. La disminución de la densidad mineral ósea (DMO) se observa en el 40-90% de las personas infectadas por el VIH, con una prevalencia de osteopenia y osteoporosis del 52 y 15%, respectivamente. Esta población de pacientes tiene un mayor riesgo de fracturas (60%) en comparación con personas no infectadas y un riesgo de fracturas vertebrales 2,3 veces mayor que en la población general. El tenofovir fumarato se asoció con un aumento de pérdida renal de fósforo e hiperparatiroidismo secundario. El efavirenz y los inhibidores de proteasas (IP) afectan el metabolismo de la vitamina D; actúan a nivel enzimático aumentando la expresión de la enzima CYP24 que lleva a producción de vitamina D inactiva. El FRAX es una herramienta sencilla y accesible, por lo que su uso está recomendado en pacientes con VIH. Además de las medidas higiénico-dietéticas, actividad física, calcio y vitamina D, el uso de bifosfonatos está indicado en el tratamiento de la osteoporosis en estos pacientes. (AU)


With the advent of antiretroviral therapy, the prognosis and survival of patients infected with the human immunodeficiency virus (HIV) have radically changed, which is why there is now evidence of an increased risk of suffering from diseases not related to HIV such as osteoporosis. The decrease in bone mineral density (BMD) is observed in 40-90% of people infected with HIV, with a prevalence of osteopenia and osteoporosis of 52 and 15%, respectively. This patient population has a 60% higher risk of fractures compared to uninfected people and a risk of vertebral fractures 2.3 times higher than in the general population. Tenofovir fumarate administration is associated with increased renal phosphorus loss and secondary hyperparathyroidism. Efavirenz and protease inhibitors (IP) affect the metabolism of vitamin D, they act at the enzymatic level by increasing the expression of the CYP24 enzyme that leads to the production of inactive vitamin D. The FRAX is a simple and accessible tool, so its use is recommended in patients with HIV and in addition to dietary hygiene measures, physical activity, calcium, and vitamin D, the use of bisphosphonates is indicated in the treatment of osteoporosis in these patients. (AU)


Subject(s)
Humans , Male , Female , Osteoporosis/prevention & control , Bone Diseases, Metabolic/prevention & control , Bone Density/drug effects , HIV Infections/complications , Osteoporosis/etiology , Osteoporosis/drug therapy , Protease Inhibitors/adverse effects , Vitamin D/metabolism , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/drug therapy , HIV Infections/drug therapy , HIV , Diphosphonates/therapeutic use , Fractures, Bone/prevention & control , Tenofovir/adverse effects
10.
Actual. osteol ; 16(1): 26-34, Ene - abr. 2020. ilus, graf
Article in Spanish | LILACS | ID: biblio-1130074

ABSTRACT

La expansión modeladora de la geometría cortical de un hueso inducida por su entorno mecánico podría ser difícil de modificar por estímulos ulteriores con diferente direccionalidad. Este estudio, que por primera vez combina datos tomográficos del peroné (pQCT) y dinamométricos de la musculatura peronea lateral, intenta demostrar que, en individuos jóvenes no entrenados, el entrenamiento en fútbol produce cambios geométricos peroneos expansivos, similares a los del rugby, que podrían interferir en los efectos de un entrenamiento ulterior direccionalmente diferente (carrera larga). Confirmando la hipótesis, los resultados indican, con evidencias originales, 1) la relevancia creciente del uso del pie (rotación externa y eversión provocadas por los peroneos laterales) para la determinación de la geometría peronea (incremento del desarrollo de los indicadores de masa y de diseño óseos), evidenciada por la secuencia creciente de efectos: carrera < fútbol < rugby; 2) la predominancia de esos efectos sobre el desarrollo centro-proximal del peroné para resistir a la flexión lateral, y en la región distal para resistir el buckling (principal sitio y causa de fractura del hueso) y 3.) la relevancia de la anticipación de esos efectos para interferir en la manifestación de los cambios producidos por un entrenamiento ulterior (carrera), cuando los del primero (fútbol) afectan la modelación cortical de modo expansivo. Esta última deducción demuestra, en forma inédita, que un cambio modelatorio expansivo tempranamente inducido sobre la estructura cortical ósea 'delimitaría el terreno'para la manifestación de cualquier otro efecto ulterior por estímulos de distinta direccionalidad. (AU)


The modeling-dependent, geometrical expansion of cortical bone induced by the mechanical environment could be hard to modify by subsequent stimulations with a different directionality. The current study aimed to demonstrate that in young, untrained individuals, training in soccer or rugby enhances the geometric properties of the fibula cortical shell in such a way that the geometrical changes could interfere on the effects of a second training in which the loads are induced in a different direction, e.g. long-distance running. The original findings reported herein confirm our hypothesis and support 1) The relevance of the use of the foot (external rotation and eversion produced by peroneus muscles) to determine fibula geometry (improved development of indicators of bone mass and design) as evidenced by the increasing nature of the effects induced by running < soccer < rugby trainings; 2) The predominance of those effects on the ability of the fibula to resist lateral bending in the centralproximal region (insertion of peroneus muscles), and to resist buckling in the distal region (the main cause and site of the most frequent bone fractures), and 3) The interaction of the effects of a previous training with those of a subsequent training with a different orientation of the loads when the former induced a modeling-dependent expansion of the cortex. Our results support the proposed hypothesis with original arguments by showing that a first, expansive effect induced on cortical bone modeling would set the stage the manifestation of any subsequent effect derived from mechanical stimuli. (AU)


Subject(s)
Humans , Male , Adolescent , Adult , Young Adult , Exercise/physiology , Fibula/growth & development , Running/physiology , Soccer/physiology , Sports/physiology , Tomography , Bone Density , Fractures, Bone/prevention & control , Muscle Strength/physiology , Muscle Strength Dynamometer , Fibula/diagnostic imaging , Cortical Bone/diagnostic imaging , Foot/growth & development , Foot/physiology , Foot/diagnostic imaging , Football/physiology
11.
Actual. osteol ; 16(1): 67-76, Ene - abr. 2020. graf, tab
Article in Spanish | LILACS | ID: biblio-1140042

ABSTRACT

La displasia fibrosa (DF) es una enfermedad infrecuente del hueso, no hereditaria, producida por una mutación activadora del gen GNAS, responsable de codificar la unidad a-estimuladora de la proteína G (Gsa). La presentación clínica de la enfermedad es muy variada, pues adopta desde formas asintomáticas hasta otras marcadamente sintomáticas. En los últimos años, el análisis exhaustivo de bases de datos de pacientes con DF ha permitido conocer más sobre su historia natural. En este artículo se revisa la información actualmente disponible sobre algunos aspectos que ayudarán al mejor enfoque clínico del paciente, como son: la utilidad clínica de los marcadores óseos, los factores pronósticos para el desarrollo de fracturas, la DF como condición predisponente para el desarrollo de tumores específicos, nuevas perspectivas sobre la fisiopatología del dolor óseo y nuevas estrategias terapéuticas. Un mayor conocimiento sobre la historia natural de esta enfermedad finalmente redundará en la mejor calidad de vida de los pacientes con DF. (AU)


Fibrous dysplasia (FD) is an infrequent, non-hereditary bone disease caused by a somatic mutation of the GNAS gene, responsible for encoding the a-subunit of the G-protein (Gsa). The clinical presentation of the disease varies greatly, with some patients being asymptomatic and others markedly symptomatic. The exhaustive analysis of the database from patients with FD has allowed to learn more about the natural history of this disease. This article reviews the current information available on the clinical utility of bone markers, the prognostic factors for the occurrence of fractures, the evidence supporting as a predisposing condition for the development of specific tumors, new perspectives on the pathophysiology of bone pain, and emerging therapeutic strategies. A greater understanding of the natural history of this disease will allow to make better medical decisions, which will ultimately contribute to improve FD patients' quality of life. (AU)


Subject(s)
Humans , Musculoskeletal Pain/physiopathology , Fibrous Dysplasia of Bone/etiology , Quality of Life , Tamoxifen/therapeutic use , Breast Neoplasms/complications , Breast Neoplasms/drug therapy , Biomarkers , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Diphosphonates/therapeutic use , Fractures, Bone/complications , Fractures, Bone/prevention & control , Musculoskeletal Pain/drug therapy , Antibodies, Monoclonal, Humanized/therapeutic use , Fibrous Dysplasia of Bone/diagnosis , Fibrous Dysplasia of Bone/physiopathology , Fibrous Dysplasia of Bone/therapy , Denosumab/administration & dosage , Denosumab/therapeutic use , Narcotics/therapeutic use
12.
Rev. Méd. Clín. Condes ; 31(1): 42-49, ene.-feb. 2020. ilus, tab
Article in Spanish | LILACS | ID: biblio-1223303

ABSTRACT

Las personas mayores con fractura de cadera tienen un aumento del riesgo de mortalidad de 5 a 8 veces por todas las causas, y un riesgo mucho mayor de institucionalización por pérdida funcional, ya que solo el 50% de los pacientes que sobreviven, recuperan la actividad de la vida diaria previa a la fractura. Las intervenciones para prevenir dichos resultados, incluyendo una segunda fractura, se transforma en el objetivo principal en estos pacientes. El modelo de atención de ortogeriatría es un enfoque de atención multidimensional para los pacientes que sufren una fractura de cadera, que por lo general, es secundario a una caída desde su propia altura, conocida como fractura por fragilidad. Este modelo de atención desarrollado por geriatras y traumatólogos con la asistencia de un equipo multidisciplinario, incluye una evaluación integral perioperatoria y un equipo de enfermería centrada en la función premórbida del paciente, la cognición, las comorbilidades, que permite crear un plan individualizado, para ser monitorizado y asegurar su cumplimiento, los primeros dos años después de la fractura. Este esquema de trabajo ha demostrado mejorar el retorno a la función previa y la disminución de la mortalidad, con un costo reducido o un aumento de utilidad expresada en calidad de vida, por lo que es la atención más rentable para los pacientes que sufren una fractura de cadera.


Older people with hip fracture have an increased risk of mortality 5 to 8 times, for all causes and a much higher risk of institutionalization due to functional loss, because only 50% of patients who survive, recover the activity of daily life before the fracture. Interventions to prevent such results, including a second fracture, become the principal objective in these patients. The orthogeriatric care model, is a multidimensional approach for patients who suffer a hip fracture, which is usually secondary to a fall from their own height, known as a fragility fracture. This model of care developed by geriatricians and traumatologists with help of a multidisciplinary team, includes a comprehensive perioperative assessment and a nursing team focused on the premorbid patient state, cognition, comorbidities, which allows creating an individualized plan, to be monitored and ensure compliance, the first 2 years. This work scheme has been shown to improve the return of the function and the reduction of mortality at a reduced cost or an expressed utility in quality of life, making it the most cost-effective care for patients suffering from a hip fracture.


Subject(s)
Humans , Aged , Fractures, Bone/prevention & control , Fractures, Bone/epidemiology , Geriatrics/organization & administration , Patient Care Team , Frail Elderly , Hip Fractures/surgery , Hip Fractures/economics
13.
Actual. osteol ; 16(3): 188-210, 2020. ilus, tab
Article in Spanish | LILACS | ID: biblio-1253839

ABSTRACT

Los micro-ARNs (miARNs) son pequeñas moléculas de ARN no codificante (de aproximadamente 15-25 nucleótidos), que regulan la expresión de genes involucrados en numerosas funciones biológicas, a través de la inhibición o degradación de un ARN mensajero diana. La homeostasis ósea se mantiene por el balance entre la formación osteoblástica y la resorción osteoclástica. La sobreexpresión o inhibición de miARNs específicos afecta la proliferación, diferenciación y actividad de osteoblastos, osteocitos y osteoclastos. Estas acciones son llevadas a cabo modulando la expresión de distintos factores transcripcionales y moléculas de señalización de las vías esenciales para la osteoblastogénesis u osteoclastogénesis. Estos efectos modifican el balance entre la formación y la resorción, determinando cambios en la homeostasis ósea. Esta revisión enumera una serie de miARNs que participan en la homeostasis ósea. Profundizando en el conocimiento de los mecanismos por medio de los cuales los miARNs actúan sobre el hueso, podrían revelarse nuevos usos potenciales futuros, entre los que se encuentran su utilidad como nuevos biomarcadores óseos o como agentes terapéuticos para el tratamiento de trastornos metabólicos óseos, pérdida de masa ósea o enfermedades óseas. (AU)


MicroRNAs (miRNAs) are endogenous small noncoding RNA molecules (of approximately 15­25 nucleotides), which regulate the expression of genes controlling numerous biological functions, through the inhibition or degradation of the target messenger RNA. Bone homeostasis is maintained by a balance between osteoblastic bone formation and osteoclastic bone resorption. The overexpression or inhibition of specific miRNAs affects cell proliferation, differentiation and activity of osteoblast, osteocytes and osteoclast. This action is done by modulating the expression of different transcription factors and signaling molecules of the most relevant pathways of osteoblastogenesis or osteoclastogenesis. This effect is able to modify the balance between bone formation and resorption, determining changes in bone homeostasis. The present review is an overview of a series of miRNAs involved in bone homeostasis. An in depth knowledge of the mechanisms by which miRNAs act on bone may reveal potential uses in the future as new bone biomarkers or therapeutic agents for treating metabolic bone disorders, bone loss and bone diseases. (AU)


Subject(s)
Humans , Bone Remodeling , MicroRNAs/therapeutic use , Osteoblasts , Osteoclasts , Osteocytes , Skeleton/metabolism , Bone Diseases/therapy , Bone Resorption/therapy , Biomarkers , MicroRNAs/physiology , Fractures, Bone/prevention & control
14.
Actual. osteol ; 15(2): 94-102, mayo - ago. 2019. tab.
Article in Spanish | LILACS | ID: biblio-1048478

ABSTRACT

El propósito de la terapia en el desorden del metabolismo óseo mineral asociado a la enfermedad renal crónica (IRC) consiste en restaurar el balance mineral, y, en la osteoporosis, mantener o aumentar la masa ósea. Ambas terapias tratan de evitar la fractura ósea. La mayoría de los osteoactivos están contraindicados en la insuficiencia renal crónica avanzada (estadios 4 y 5), y las terapias son empíricas. Algunos autores opinan que sin anomalías bioquímicas del desorden del metabolismo óseo mineral asociado a la enfermedad renal crónica avanzada se podría intentar el tratamiento estándar para la osteoporosis. Antes de intentar la terapia osteoactiva se debe corregir el desorden mineral óseo que pudiera presentarse asociado a la IRC, y en la indicación del tipo de osteoactivo se sugiere seleccionar al paciente según su estado óseo. Se aconseja que la administración de los antirresortivos se realice a dosis menores con respecto a los que tienen mejor función renal junto con aportes adecuados de calcio y vitamina D, antes y durante el tratamiento para prevenir el riesgo de severas hipocalcemias y un efecto óseo excesivo. Se presenta el caso clínico de una mujer de 65 años, con diagnóstico de osteoporosis de etiología multifactorial, fractura de pelvis, múltiples fracturas vertebrales e insuficiencia renal crónica avanzada, entre otras comorbilidades, y probable enfermedad ósea adinámica. Recibió inicialmente terapia con teriparatide y luego con denosumab, complicándose con hipocalcemia asintomática. (AU)


The purpose of therapy for the bone mineral metabolism disorder associated with chronic kidney disease is to restore the mineral balance; and to maintain or increase bone mass in osteoporosis. The goal of both types of therapy is to avoid bone fractures. Most antiosteoporotic drugs are contraindicated in advanced chronic renal failure (CRF) stages 4 and 5, and the therapies are empirical. Some authors believe that without biochemical abnormalities of the mineral bone metabolism disorder associated with advanced chronic kidney disease, standard treatment for osteoporosis could be attempted. Before attempting antiosteoporotic therapy, the bone mineral disorder that may be associated with CRF must be corrected, and in the indication of the type drug it is suggested that the patient be selected according to their bone status. It is advised that the administration of anti-resorptives be performed at lower doses in individuals with poor renal function compared to those with better renal function together with adequate calcium and vitamin D, before and during treatment to prevent the risk of severe hypocalcemia, and an excessive bone effect. We present the clinical case of a 65-year-old woman with a diagnosis of osteoporosis of multifactorial etiology, pelvic fracture, multiple vertebral fractures and advanced chronic renal failure, among other comorbidities and probable adynamic bone disease. The patient received initial therapy with teriparatide and followed by denosumab administration and exhibited asymptomatic hypocalcemia. (AU)


Subject(s)
Humans , Female , Aged , Chronic Kidney Disease-Mineral and Bone Disorder/drug therapy , Fractures, Bone/prevention & control , Osteoporosis/therapy , Chronic Kidney Disease-Mineral and Bone Disorder/complications , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/therapy , Vitamin D/administration & dosage , Vitamin D/therapeutic use , Calcium/administration & dosage , Calcium/therapeutic use , Alendronate/therapeutic use , Teriparatide/administration & dosage , Teriparatide/adverse effects , Teriparatide/therapeutic use , Diphosphonates/administration & dosage , Diphosphonates/adverse effects , Diphosphonates/therapeutic use , Cinacalcet/therapeutic use , Risedronic Acid/therapeutic use , Denosumab/administration & dosage , Denosumab/adverse effects , Denosumab/therapeutic use , Hypocalcemia/prevention & control
16.
Clinics ; 74: e829, 2019. tab, graf
Article in English | LILACS | ID: biblio-1001830

ABSTRACT

OBJECTIVE: To test whether swimming training benefits femoral neck strength in young diabetic rats under insulin therapy. METHODS: A total of 60 male Wistar rats (age: 40 days) were divided equally into the following six groups: control sedentary, control exercise, diabetic sedentary, diabetic exercise, diabetic sedentary plus insulin and diabetic exercise plus insulin. Diabetes was induced with a unique intraperitoneal injection (60 mg/kg body weight) of streptozotocin. Seven days after the injection and after 12 hours of fasting, the animals with blood glucose levels ≥300 mg/dL were considered diabetic. Seven days after the induction of diabetes, the animals in the exercise groups were subjected to progressive swimming training (final week: 90 min/day; 5 days/week; 5% load) for eight weeks. The animals in the insulin groups received a daily dose of insulin (2-4 U/day) for the same period. RESULTS: Severe streptozotocin-induced diabetes reduced the structural properties of the femoral neck (trabecular bone volume, trabecular thickness and collagen fiber content). The femoral neck mechanical properties (maximum load and tenacity) were also impaired in the diabetic rats. Insulin therapy partially reversed the damage induced by diabetes on the structural properties of the bone and mitigated the reductions in the mechanical properties of the bone. The combination of therapies further increased the femoral neck trabecular bone volume (∼30%), trabecular thickness (∼24%), collagen type I (∼19%) and type III (∼13%) fiber contents, maximum load (∼25%) and tenacity (∼14%). CONCLUSIONS: Eight weeks of swimming training potentiates the recovery of femoral neck strength in young rats with severe streptozotocin-induced diabetes under insulin therapy.


Subject(s)
Animals , Male , Swimming/physiology , Diabetes Mellitus, Experimental/physiopathology , Diabetes Mellitus, Experimental/drug therapy , Exercise Therapy/methods , Femur Neck/physiopathology , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Physical Conditioning, Animal/physiology , Time Factors , Blood Glucose/analysis , Body Weight/physiology , Reproducibility of Results , Collagen/analysis , Rats, Wistar , Streptozocin , Fractures, Bone/physiopathology , Fractures, Bone/prevention & control , Cancellous Bone/physiopathology
17.
Actual. osteol ; 14(3): 205-218, sept. - dic. 2018. ilus., graf.
Article in Spanish | LILACS | ID: biblio-1052695

ABSTRACT

La diabetes es una enfermedad crónica asociada con importantes comorbilidades. El sistema esquelético parece ser un objetivo adicional de daño mediado por diabetes. Se acepta que la diabetes tipo 1 y tipo 2 se asocian con un mayor riesgo de fractura ósea. Varios estudios han demostrado que los cambios metabólicos causados por la diabetes pueden influir en el metabolismo óseo disminuyendo la calidad y la resistencia del hueso. Sin embargo, los mecanismos subyacentes no se conocen por completo pero son multifactoriales y, probablemente, incluyen los efectos de la obesidad, hiperglucemia, estrés oxidativo y acumulación de productos finales de glicosilación avanzada. Estos darían lugar a un desequilibrio de varios procesos y sistemas: formación de hueso, resorción ósea, formación y entrecruzamiento de colágeno. Otros factores adicionales como la hipoglucemia inducida por el tratamiento, ciertos medicamentos antidiabéticos con un efecto directo sobre el metabolismo óseo y mineral, así como una mayor propensión a las caídas, contribuirían al aumento del riesgo de fracturas en pacientes con diabetes mellitus. Esta revisión tiene como objetivo describir los mecanismos fisiopatológicas subyacentes a la fragilidad ósea en pacientes diabéticos. (AU)


Diabetes is a chronic disease associated with important comorbidities. The skeletal system seems to be an additional target of diabetes mediated damage. It is accepted that type 1 and type 2 diabetes are associated with an increased risk of bone fracture. Several studies have shown that metabolic changes caused by diabetes can influence bone metabolism by decreasing bone quality and resistance. However, the underlying mechanisms are not completely known but they are multifactorial and probably include the effects of obesity, hyperglycemia, oxidative stress and accumulation of advanced glycosylation end products. These would lead to an imbalance of several processes and systems: bone formation, bone resorption, formation and collagen crosslinking. Other additional factors such as treatment-induced hypoglycemia, certain antidiabetic medications with a direct effect on bone and mineral metabolism, as well as an increased propensity for falls, would contribute to the increased risk of fractures in patients with diabetes mellitus. This review aims to describe the pathophysiological mechanisms underlying bone fragility in diabetic patients. (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Osteogenesis Imperfecta/physiopathology , Diabetes Mellitus/physiopathology , Osteogenesis Imperfecta/metabolism , Osteogenesis Imperfecta/drug therapy , Osteoporosis/diagnosis , Bone and Bones/metabolism , Glycosylation , Risk Factors , Oxidative Stress , Diabetes Mellitus/metabolism , Diabetes Mellitus/epidemiology , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 2/complications , Fractures, Bone/complications , Fractures, Bone/prevention & control , Hyperglycemia/complications , Hypoglycemia/chemically induced , Hypoglycemic Agents/adverse effects , Obesity/complications
18.
Actual. osteol ; 14(3): 178-183, sept. - dic. 2018. graf.
Article in Spanish | LILACS | ID: biblio-1049692

ABSTRACT

Para analizar el impacto directo de la musculatura sobre la estructura ósea se determinaron el área (CtA), la densidad mineral ósea volumétrica (vDMOc) y los momentos de inercia corticales para flexión anteroposterior y lateral (MIap, MIlat) ajustados a CtA, y las relaciones entre MI y vDMOc (de Ê»distribución/calidadʼ, d/c, que describen la eficiencia de la optimización biomecánica del diseño cortical por el mecanostato) en 18 cortes seriados a lo largo de todo el peroné del lado hábil (pQCT), y la fuerza de salto y de rotación externa del pie (dinamometría computarizada) de 22 hombres sanos de 18 a 33 años entrenados en fútbol competitivo por más de 4 años, y de 9 controles etarios no entrenados. Los entrenados tuvieron valores más altos de MI en función de la fuerza de rotación del pie (no de salto), con un ajuste homogéneo para MIap pero variable (más pobre distalmente y más alto proximalmente, en la región de inserción de los peroneos) para MIlat, coincidiendo este último con pobres ajustes de las relaciones d/c (efecto arquitectónico independiente de la rigidez del tejido). Esto evidencia la influencia directa de la tracción de la musculatura peronea sobre la estructura cortical proximal subyacente del hueso y también sugiere que el mecanostato procedería, en este caso, fuera de su conocida concepción como mecanismo regulatorio de la resistencia ósea. (AU)


To analyze the direct impact of muscle contractions on the structure of bones, we determined the cortical cross-sectional area (CtA), volumetric mineral density (vBMDc) and the CtA-adjusted moments of inertia for anterior-posterior and lateral bending (MIap, MIlat), and the ʻdistribution/qualityʼ (d/c) relationships between MIs and vBMDc (which describe the efficiency of the biomechanical optimization of cortical design by bone mechanostat) in 18 serial scans taken throughout the fibula of the dominant side (pQCT), and the jump and the foot-lateral-rotation forces (computed dynamometry) of 22 healthy men aged 18-33 years, who had been trained in competitive soccer for more than 4 years, and of 9 untrained, agematched controls. Trained individuals showed higher MI values as a function of the rotative force of the foot (not the jumping force). The adjustment of these relationships was homogeneous for MIap throughout the bone, but variable (poorer distally and higher proximally, at the insertion area of peroneus muscles) for MIlat, this latter being paralleled by poor adjustments of the corresponding, d/c relationships (architectural effect independent of tissue stiffness). These findings,1. Show the direct influence of the traction force of peroneal muscles on proximal fibula structure close to the insertion area, and 2. Suggest that, in the studied conditions, the bone mechanostat would proceed beyond its known conception as a regulatory mechanism of structural bone strength. (AU)


Subject(s)
Fibula/physiopathology , Musculoskeletal System/diagnostic imaging , Musculoskeletal Physiological Phenomena , Soccer , Biomechanical Phenomena/physiology , Bone and Bones/physiopathology , Exercise , Fractures, Bone/prevention & control , Fibula/anatomy & histology , Foot/diagnostic imaging , Muscles/physiopathology
19.
Rev. Soc. Bras. Clín. Méd ; 16(1): 7-12, 20180000. tab
Article in Portuguese | LILACS | ID: biblio-884976

ABSTRACT

OBJETIVO: Comparar resultados de densitometrias ósseas e do risco de fratura pela plataforma Fracture Risk Assessment Tool® (FRAX®). Métodos: Estudo observacional, transversal, de natureza quantitativa, realizado por meio da análise de prontuários de indivíduos que realizaram densitometria óssea e seus respectivos laudos, com cálculo posterior do risco de fratura maior e de quadril nos próximos 10 anos pela FRAX®. RESULTADOS: A média de idade foi de 60,19±9,44 anos, e houve predomínio de mulheres (96,5%). Dos indivíduos, 1,1% foi classificado como com risco de fratura maior e 9,1% com risco de fratura de quadril. A osteoporose foi encontrada em 12,4% da amostra, com predomínio nos pacientes mais idosos, e a coluna foi o sítio mais comum (53,7%). Admitindo-se a densitometria óssea como padrão-ouro para diagnóstico de osteoporose, a sensibilidade da plataforma para detectar risco de fratura maior foi 4,5%. Observou-se correlação positiva entre idade e risco de fratura, e negativa entre idade e T-score. CONCLUSÃO: Foi baixa a sensibilidade da plataforma, e não foi importante a relação entre os resultados da densitometria óssea e da FRAX®, sugerindo que esta ferramenta não se mostrou adequada para ser inserida como método de rastreio para osteoporose na população estudada.(AU)


OBJECTIVES: To compare the results of bone densitometry and fracture risk through the platform Fracture Risk Assessment Tool (FRAX®). METHODS: This is a cross-sectional, observational study of quantitative approach performed through the analyses of medical records of individuals who underwent bone densitometry and their respective reports, with a posterior calculation of the risk of major and hip fracture in the next 10 years through FRAX®. RESULTS: The mean age was 60.19±9.44 years, with a predominance of women (96.5%). Of the individuals, 1.1% were classified as having a major fracture risk, and 9.1% as having a hip fracture risk. Osteoporosis was found in 12.4% of the sample, with predominance in the older patients, and the spine was the most common site (53.7%). Assuming bone densitometry as the gold standard for diagnosis of osteoporosis, the sensitivity of the platform to detect major fracture risk was 4.5%. There was a positive correlation between age and fracture risk, and a negative correlation between age and t-score. CONCLUSION: The platform showed low sensitivity, and the relationship between the results of the bone densitometry and FRAX® was not significant, suggesting that this tool is not adequate to be inserted as a screening method for osteoporosis in the studied population.(AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Bone Density/physiology , Fractures, Bone/prevention & control , Osteoporosis/diagnostic imaging , Osteoporotic Fractures/prevention & control , Densitometry/methods , Risk Factors
20.
Actual. osteol ; 14(1): 10-21, Ene - Abr. 2018. ilus, graf, tab
Article in Spanish | LILACS | ID: biblio-1116424

ABSTRACT

La suplementación con calcio reduciría, sola o asociada a otra medicación para osteoporosis, la pérdida de masa ósea y el riesgo de fracturas. Sin embargo, su tasa de adherencia es baja debido a la poca tolerancia. Objetivo: comparar la tasa de absorción neta de calcio entre dos formulaciones distintas de carbonato de calcio (500 mg): comprimidos vs. mousse. Material y métodos: 11 pruebas fueron realizadas en mujeres posmenopáusicas de 58,9±3 años. El diseño fue exploratorio abierto, aleatorizado, prospectivo cruzado de fase 4. Intervención: las participantes fueron aleatorizadas en dos grupos para recibir las dos formulaciones previa suplementación con vitamina D3. La tasa de absorción neta de calcio fue estudiada por la prueba de inhibición de hormona paratiroidea (PTH). Se obtuvieron muestras de sangre: basal y en la 1a, 2a y 3a hora posadministración del calcio asignado, y de orina de 2 horas basal y al final de la prueba. Determinaciones bioquímicas: calcio, fósforo, albúmina, 25-hidroxivitamina D y hormona paratiroidea intacta y calciuria. Análisis estadístico: método de los trapecios para calcular el área bajo la curva (AUC) de la concentración de calcio en el tiempo (R Development Core Team (2008). http://www.Rp-project.org) y Anova con dos términos de error para evaluar el efecto secuencia, período y formulación. Resultados: la mayor inhibición de PTH se observó a dos horas de la toma de ambas formulaciones (comprimidos -39,2% vs. mousse -38,0%; p=ns), con similar AUC0-3 h (comprimidos 3,35; IC 95%: 3,32; 3,37 vs. mousse 3,36; IC 95%: 3,33; 3,38). Cuando analizamos tolerancia y preferencias no se observaron diferencias estadísticamente significativas entre ambas formulaciones. Conclusión: el carbonato de calcio en mousse mostró similar tasa de absorción intestinal, preferencia y tolerancia gastrointestinal que en comprimido. (AU)


Calcium supplementation, administered alone or in combination with a specific medication for osteoporosis, would reduce bone mass loss and fracture risk in postmenopausal women. However, the adherence rate to calcium supplements is low, mainly due to low tolerance. Objective: comparisson of net calcium absorption rate between two different pharmaceutical formulations of calcium carbonate (PFCa) in postmenopausal women. Materials and Methods: 11 tests were performed in postmenopausal women aged 58.9±3 yrs. Design: Comparative, randomized, prospective, open-label exploratory crossover study of calcium mousse versus calcium pills. Intervention: Participants were randomized in 2 groups to receive the 2 different PFCa (500mg): pills vs. mousse, with previous vitamin D3 supplementation. The parathyroid hormone (PTH) inhibition test and the area-under-thecurve (AUC) of calcium were analyzed. Blood samples were taken at baseline and 1, 2 and 3 hrs after intake of the assigned PFCa. Urine samples (2hs) were obtained at -baseline, after 2hs of PFCa intake and at the end of the test. Biochemical Determinations: Serum: calcium, phosphorus, albumin, 25-hydroxyvitamin D, and intact PTH. In urine: calcium. Statistical Analysis: The trapezoid rule was applied to assess AUC in time (R Development Core Team (2008). http://www.Rp-project.org). An ANOVA model with 2 error terms was used to assess the effect of sequence, period, and formulation. Results: The highest inhibition PTH rates were observed after 2 hrs of PFCa (pills -39.2% vs. mousse -38.0%; p=ns). The AUC0-3hrs for both PFCa was similar (pills 3.35; 95%CI: 3.32; 3.37 vs. mousse 3.36; 95%CI: 3.33; 3.38). No statistically significant differences were observed when we analyze tolerance and predilection. Conclusion: The calcium carbonate in mousse showed an adequate rate of intestinal absorption, similarly predilection and gastrointestinal tolerance than the pill presentation. (AU)


Subject(s)
Humans , Female , Middle Aged , Calcium Carbonate/pharmacokinetics , Osteoporosis, Postmenopausal/prevention & control , Calcium/pharmacokinetics , Parathyroid Hormone/analysis , Achlorhydria , Calcitriol/pharmacokinetics , Calcium Carbonate/administration & dosage , Calcium Carbonate/therapeutic use , Body Mass Index , Bone Density , Nutrition Assessment , Osteoporosis, Postmenopausal/diet therapy , Osteoporosis, Postmenopausal/drug therapy , Mass Screening , Calcium/deficiency , Postmenopause/drug effects , Postmenopause/blood , Cholecalciferol/administration & dosage , Cholecalciferol/adverse effects , Cross-Over Studies , Calcium Citrate/therapeutic use , Fractures, Bone/prevention & control , Estrogens/deficiency , Gastrointestinal Absorption/drug effects , Treatment Adherence and Compliance , Anabolic Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL